Using Acceleration Levers to Expedite Late-Phase CMC for Proteins

The biopharma industry is increasingly embracing the concept of ‘Acceleration Levers’ to optimize timelines and expedite time to market, as late-phase chemistry, manufacturing and controls (CMC) programs often face delays that jeopardize speed to market and strain development resources. This webinar explores strategies for reducing late-phase CMC timelines for mammalian and microbial-derived therapeutic proteins.

The featured speaker will explore the definition of an acceleration lever and examine how its application can vary based on differing risk profiles and perspectives. The speaker will also discuss key strategic levers that can drive acceleration, highlighting their potential impact on timelines and success in therapeutic protein development.

Register for this webinar to learn how to apply acceleration levers in late phase CMC to reduce timelines and improve program efficiency.

Keywords: CDMO/CMO, CMC, Commercial Manufacturing, Commercialization/HEOR/Market Access, Drug Development, Drug Manufacturing, Process Development, Protein, Protein Therapeutic, Risk Assessment